Korro Bio, Inc. filings document the regulatory record of a biopharmaceutical company developing RNA-editing genetic medicines through its OPERA® platform. Its 8-K reports disclose operating and financial results, corporate presentations, clinical and regulatory program updates, capital-structure activity, and material events tied to its RNA-editing pipeline.
The company’s filings also cover proxy governance, executive compensation, equity incentive and inducement arrangements, employment agreements, and material collaboration and license agreements. Program-related disclosures focus on KRRO-121, hyperammonemia in urea cycle disorders and hepatic encephalopathy, GalNAc-conjugated oligonucleotide research, alpha-1 antitrypsin deficiency, risk factors, and the financing and governance framework supporting Korro Bio’s development-stage operations.
Korro Bio, Inc. Senior Vice President of Finance Oliver Dolan reported an open-market sale of 3,383 shares of common stock on June 16, 2026 at a weighted-average price of $10.83 per share. According to the footnotes, this was a mandatory sale solely to cover tax withholding obligations arising from the vesting and settlement of restricted stock units (RSUs) granted under the company’s 2023 Stock Option and Incentive Plan.
After this transaction, Dolan holds 18,099 shares of common stock directly, which includes 10,741 shares issuable upon settlement of an RSU that is scheduled to vest on December 15, 2026, provided he maintains a continuous service relationship through that date.
Korro Bio director Ali Behbahani received a grant of stock options covering 14,677 shares of common stock at an exercise price of $10.59 per share. These options were awarded at no upfront cost and expire on June 9, 2036.
The options vest in full on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, subject to his continued service as a non-employee director. Following this award, Behbahani holds 14,677 stock options directly.
Korro Bio, Inc. director Rachel Meyers received a grant of stock options as part of her compensation. The award covers 14,677 options to purchase Common Stock at an exercise price of $10.59 per share, all held directly after the transaction.
These options vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual meeting of stockholders, provided she continues serving as a non-employee director through that date. The options are scheduled to expire on June 9, 2036, giving a long-dated incentive aligned with the company’s share price performance.
Korro Bio, Inc. reported that director Nessan Bermingham received a stock option grant covering 14,677 shares of common stock. The option has an exercise price of $10.59 per share and expires on June 9, 2036. The option vests in full on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, subject to his continued service as a non-employee director.
Korro Bio director Katharine Knobil received a grant of stock options covering 14,677 shares of common stock at an exercise price of $10.59 per share. These options vest in full on the earlier of one year from the grant date or the next annual stockholder meeting, subject to her continued service as a non-employee director, and will expire on June 9, 2036.
Korro Bio director Jean Francois Formela received a stock option grant as equity compensation. The award covers 14,677 shares of common stock at an exercise price of $10.59 per share and expires on June 9, 2036. The option vests in full on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, provided he continues serving as a non-employee director through that vesting date.